|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/19/16 AbbVie Inc. 10-K 12/31/15 97:20M Toppan Merrill-FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.54M
2: EX-10.4 Material Contract HTML 124K
3: EX-10.5 Material Contract HTML 123K
4: EX-10.6 Material Contract HTML 92K
5: EX-10.8 Material Contract HTML 134K
7: EX-21 Subsidiaries List HTML 128K
8: EX-23 Consent of Experts or Counsel HTML 29K
6: EX-12 Statement re: Computation of Ratios HTML 35K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
12: EX-32.2 Certification -- §906 - SOA'02 HTML 28K
19: R1 Document and Entity Information HTML 53K
20: R2 Consolidated Statements of Earnings HTML 80K
21: R3 Consolidated Statements of Earnings HTML 31K
(Parenthetical)
22: R4 Consolidated Statements of Comprehensive Income HTML 48K
23: R5 Consolidated Statements of Comprehensive Income HTML 39K
(Parenthetical)
24: R6 Consolidated Balance Sheets HTML 103K
25: R7 Consolidated Balance Sheets (Parenthetical) HTML 35K
26: R8 Consolidated Statements of Equity HTML 87K
27: R9 Consolidated Statements of Cash Flows HTML 129K
28: R10 Background and Basis of Presentation HTML 38K
29: R11 Summary of Significant Accounting Policies HTML 125K
30: R12 Supplemental Financial Information HTML 110K
31: R13 Earnings Per Share HTML 34K
32: R14 Licensing, Acquisitions and Other Arrangements HTML 114K
33: R15 Collaboration with Janssen Biotech, Inc. HTML 33K
34: R16 Goodwill and Intangible Assets HTML 134K
35: R17 Restructuring Plans HTML 59K
36: R18 Debt, Credit Facilities, and Commitments and HTML 192K
Contingencies
37: R19 Financial Instruments and Fair Value Measures HTML 495K
38: R20 Post-Employment Benefits HTML 597K
39: R21 Equity HTML 332K
40: R22 Income Taxes HTML 276K
41: R23 Legal Proceedings and Contingencies HTML 44K
42: R24 Segment and Geographic Area Information HTML 145K
43: R25 Quarterly Financial Data (Unaudited) HTML 105K
44: R26 Summary of Significant Accounting Policies HTML 198K
(Policies)
45: R27 Summary of Significant Accounting Policies HTML 88K
(Tables)
46: R28 Supplemental Financial Information (Tables) HTML 116K
47: R29 Licensing, Acquisitions and other Arrangements HTML 100K
(Tables)
48: R30 Goodwill and Intangible Assets (Tables) HTML 130K
49: R31 Restructuring Plans (Tables) HTML 56K
50: R32 Debt, Credit Facilities, and Commitments and HTML 190K
Contingencies (Tables)
51: R33 Financial Instruments and Fair Value Measures HTML 489K
(Tables)
52: R34 Post-Employment Benefits (Tables) HTML 615K
53: R35 Equity (Tables) HTML 324K
54: R36 Income Taxes (Tables) HTML 279K
55: R37 Segment and Geographic Area Information (Tables) HTML 143K
56: R38 Quarterly Financial Data (Unaudited) (Tables) HTML 103K
57: R39 Background and Basis of Presentation (Details) HTML 55K
58: R40 Summary of Significant Accounting Policies HTML 32K
(Details)
59: R41 Summary of Significant Accounting Policies HTML 46K
(Details 2)
60: R42 Summary of Significant Accounting Policies HTML 75K
(Details 3)
61: R43 Supplemental Financial Information (Details) HTML 78K
62: R44 Earnings Per Share (Details) HTML 54K
63: R45 Licensing, Acquisitions and Other Arrangements HTML 109K
(Details)
64: R46 Licensing, Acquisitions and Other Arrangements HTML 107K
(Details 2)
65: R47 Licensing, Acquisitions and Other Arrangements HTML 113K
(Details 3)
66: R48 Collaboration with Janssen Biotech, Inc. (Details) HTML 54K
67: R49 Goodwill and Intangible Assets (Details) HTML 91K
68: R50 Goodwill and Intangible Assets (Details 2) HTML 33K
69: R51 Restructuring Plans (Details) HTML 29K
70: R52 Restructuring Plans (Details 2) HTML 40K
71: R53 Debt, Credit Facilities, and Commitments and HTML 135K
Contingencies (Details)
72: R54 Debt, Credit Facilities, and Commitments and HTML 80K
Contingencies (Details 2)
73: R55 Financial Instruments and Fair Value Measures HTML 69K
(Details)
74: R56 Financial Instruments and Fair Value Measures HTML 47K
(Details 2)
75: R57 Financial Instruments and Fair Value Measures HTML 79K
(Details 3)
76: R58 Financial Instruments and Fair Value Measures HTML 34K
(Details 4)
77: R59 Financial Instruments and Fair Value Measures HTML 44K
(Details 5)
78: R60 Financial Instruments and Fair Value Measures HTML 52K
(Details 6)
79: R61 Financial Instruments and Fair Value Measures HTML 69K
(Details 7)
80: R62 Post-Employment Benefits (Details) HTML 212K
81: R63 Post-Employment Benefits (Details 2) HTML 141K
82: R64 Post-Employment Benefits (Details 3) HTML 30K
83: R65 Equity (Details) HTML 164K
84: R66 Equity (Details 2) HTML 82K
85: R67 Equity (Details 3) HTML 99K
86: R68 Equity (Details 4) HTML 62K
87: R69 Income Taxes (Details) HTML 126K
88: R70 Income Taxes (Details 2) HTML 34K
89: R71 Income Taxes (Details 3) HTML 39K
90: R72 Income Taxes (Details 4) HTML 58K
91: R73 Legal Proceedings and Contingencies (Details) HTML 55K
92: R74 Segment and Geographic Area Information (Details) HTML 85K
93: R75 Segment and Geographic Area Information (Details HTML 73K
2)
94: R76 Quarterly Financial Data (Unaudited) (Details) HTML 106K
96: XML IDEA XML File -- Filing Summary XML 169K
95: EXCEL IDEA Workbook of Financial Reports XLSX 129K
13: EX-101.INS XBRL Instance -- abbv-20151231 XML 6.85M
15: EX-101.CAL XBRL Calculations -- abbv-20151231_cal XML 289K
16: EX-101.DEF XBRL Definitions -- abbv-20151231_def XML 1.10M
17: EX-101.LAB XBRL Labels -- abbv-20151231_lab XML 2.45M
18: EX-101.PRE XBRL Presentations -- abbv-20151231_pre XML 1.64M
14: EX-101.SCH XBRL Schema -- abbv-20151231 XSD 263K
97: ZIP XBRL Zipped Folder -- 0001047469-16-010239-xbrl Zip 342K
 | Download this zipped .zip folder |
| Files: | abbv-20151231.xml abbv-20151231.xsd abbv-20151231_cal.xml abbv-20151231_def.xml abbv-20151231_lab.xml abbv-20151231_pre.xml |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/19/21 AbbVie Inc. 10-K 12/31/20 117:22M |